Stocktoria
Indivior Pharmaceuticals, Inc. INDV
Indivior Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.1B |
| Gross profit | $994.0M | $957.0M | $919.0M |
| SG&A expense | $634.0M | $612.0M | $565.0M |
| Operating income | $262.0M | $38.0M | -$152.0M |
| Income tax | $29.0M | $13.0M | -$19.0M |
| Net income | $210.0M | $7.0M | -$126.0M |
| EPS (diluted) | $1.64 | $0.05 | $-0.92 |
| Operating cash flow | -$27.0M | $36.0M | -$300.0M |
| Free cash flow | -$93.0M | $7.0M | -$308.0M |
| Cash & equivalents | $195.0M | $319.0M | $316.0M |
| Inventory | $153.0M | $167.0M | $126.0M |
| Total assets | $1.2B | $1.3B | $1.8B |
| Total liabilities | $1.3B | $1.7B | $1.9B |
| Shareholders' equity | -$98.0M | -$337.0M | -$184.0M |
Growth · year-over-year · Revenue CAGR 6.5%
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | +4.3% | +8.7% | — |
| Net income growth | +2900.0% | — | — |
| EPS growth | +3180.0% | — | — |
| Free cash flow growth | -1428.6% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.